Dupilumab Beyond the Airway: Decreased Morbidity in a Real‐World Analysis
International Forum of Allergy & Rhinology · 2026
DOI: 10.1002/alr.70111 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, 2026. Verfasst von Emma J Anisman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Asthma, Nasal Polyps, Rhinosinusitis. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Post hoc analyses of clinical trials have characterized dupilumab's adverse effects, yet the real‐world impact in chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma is not well described. This study aims to characterize the risks of lymphoma, cardiovascular events, eosinophilia, joint pain, inflammatory arthritis, and sleep apnea in dupilumab‐treated CRSwNP and/or asthma patients compared to those not taking dupilumab, and to other biologics.
Methods
This retrospective cohort study used TriNetX, a de‐identified database containing over 100 million patient records. Demographics and adverse effects associated with immunotherapy use were collected.
Results
We identified 21,249 dupilumab‐treated CRSwNP and/or asthma patients. After matching for demographics, comorbid conditions, and medication use, dupilumab was associated with a lower risk of acute myocardial infarction (RR 0.538, 95% CI 0.435–0.665), pulmonary embolism (RR 0.639, 95% CI 0.500–0.817), cerebral infarction (RR 0.716, 95% CI 0.580–0.884), venous thrombosis (RR 0.625, 95% CI 0.511–0.763), cardiovascular disease (RR 0.733, 95% CI 0.678–0.791), and sleep apnea (RR 0.891, 95% CI 0.818–0.970), with a higher risk of eosinophilia (RR 3.157, 95% CI 2.606–3.826), versus no biologic. Dupilumab was associated with a similar risk of lymphoma and musculoskeletal outcomes. Compared to omalizumab and mepolizumab, dupilumab showed a more favorable musculoskeletal and cardiovascular profile, while it demonstrated a largely similar profile to tezepelumab.
Conclusions
Despite eosinophilia, dupilumab was associated with decreased risk of major cardiovascular, thromboembolic, and sleep apnea outcomes in CRSwNP and asthma. These findings suggest dupilumab may confer protection against adverse outcomes beyond respiratory symptom control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
- Department of Pulmonary and Critical Care Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Emma J Anisman
Zitieren
APA
Anisman, E. J., Short, S., Tam, E., Bitner, B. F., Alani, A., Rosen, M., Rabinowitz, M., Evertz, D. P., Toskala, E., & Nyquist, G. G. (2026). Dupilumab Beyond the Airway: Decreased Morbidity in a Real‐World Analysis. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.70111
Vancouver
Anisman EJ, Short S, Tam E, Bitner BF, Alani A, Rosen M, et al. Dupilumab Beyond the Airway: Decreased Morbidity in a Real‐World Analysis. International Forum of Allergy & Rhinology. 2026. doi:10.1002/alr.70111
BibTeX
@article{Anisman2026,
author = {Anisman, Emma J and Short, Spencer and Tam, Emma and Bitner, Benjamin F and Alani, Abdulghafoor and Rosen, Marc and Rabinowitz, Mindy and Evertz, Damaris Pena and Toskala, Elina and Nyquist, Gurston G},
title = {Dupilumab Beyond the Airway: Decreased Morbidity in a Real‐World Analysis},
journal = {International Forum of Allergy & Rhinology},
year = {2026},
doi = {10.1002/alr.70111}
}
EUVIMED